Longitudinal multi-omics monitoring paves the way for early pancreatic cancer diagnosis

A new case report published in the peer-reviewed OMICS: A Journal of Integrative Biology describes how longitudinal multi-omics monitoring (LMOM) helped to detect a precancerous pancreatic tumor and led to a successful surgical intervention. 

The patient had undergone annual blood-based LMOM, in which 143 endogenous metabolites in serum and a panel of 140 proteins in plasma were measured. David Wishart, PhD, from the University of Alberta, and coauthors, reported that three to four years after annual LMOM had begun, dramatic changes in the metabolomics and proteomics results prompted further clinical diagnostic testing for pancreatic cancer. A 2.6 cm lesion was detected in the tail of the patient's pancreas. 

"This case report illustrates the potentials of blood LMOM for precision/personalized medicine, and new ways of thinking medical innovation for a potentially life-saving early diagnosis of pancreatic cancer," stated the investigators.

Longitudinal multi-omics monitoring offers promise for systems medicine and warrants translational research for early detection and clinical management of pancreatic cancer."

Vural Özdemir MD, PhD, DABCP, MA, Editor-in-Chief , OMICS

Source:
Journal reference:

Anwar, M. A., et al. (2024). Blood-Based Multiomics-Guided Detection of a Precancerous Pancreatic Tumor. Omics. doi.org/10.1089/omi.2023.0278.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Blood microRNAs can predict conversion from mild cognitive impairment to dementia due to Alzheimer’s disease